Autophagy: From Model Systems to Therapeutic Opportunities

Organizer(s): Vojo Deretic, Li Yu and Leon O. Murphy

This activity is supported by an educational grant from Celgene Corporation

Summary of Meeting:

Autophagy is a homeostatic process strategically positioned at the intersection of metabolism and intracellular quality control, with broad physiological and medical manifestations ranging from metabolic imbalance to neurodegeneration, infections, immune disorders, cancer and aging. In yeast, the formation and organization of the autophagosomal apparatus follows a highly prescribed sequence, starting with the pre-autophagosomal structure and ending in autophagosomal fusion with the yeast vacuole. However, in other model organisms, as well as in mammals, the autophagy machinery and its regulators show both similarities and notable differences relative to yeast. The goals/aims of the conference are: 1) Compare and contrast autophagy in yeast and higher organisms with a focus on both the shared regulators and on those factors that have no counterparts in yeast. 2) Cover the intersection of autophagy with energy metabolism, innate immune signaling and endomembrane damage. 3) Cover how signaling cascades regulate the process of selective autophagy whereby substrates are recruited to forming autophagosomes by receptors and molecular tags such as ubiquitin, galectins, or through other modalities. The conference will cover fundamental principles as outlined above and how they apply to basic and translational aspects of human disease. Intersections with several other stress response processes will be addressed.

Scholarship Deadline: October 23 2018

Discounted Abstract Deadline: October 23 2018

Abstract Deadline: November 15 2018

Discounted Registration Deadline: December 13 2018

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Denali Therapeutics Inc.

Novartis Institutes for BioMedical Research

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA232432-01
Funding for this conference was made possible (in part) by 1 R13 CA232432-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations